<DOC>
	<DOCNO>NCT00022594</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness liposomal lurtotecan treating patient metastatic locally recurrent head neck cancer .</brief_summary>
	<brief_title>Liposomal Lurtotecan Treating Patients With Metastatic Locally Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic activity lurtotecan liposome patient metastatic loco-regionally recurrent squamous cell carcinoma head neck . - Determine objective response , duration response , time progression patient treat drug . - Determine toxicity profile drug patient . - Determine possible pharmacokinetic/pharmacodynamic relationship drug patient . OUTLINE : This multicenter study . Patients stratify accord presence target lesion previously irradiate field ( within v outside ) . Patients receive lurtotecan liposome IV 30 minute day 1 8 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 6 week . PROJECTED ACCRUAL : A total 38-72 patient ( 19-36 per stratum ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Metastatic locoregionally recurrent disease No undifferentiated nonkeratinizing carcinoma include lymphoepitheliomas No tumor nasal paranasal cavity nasopharynx Measurable disease No clinical symptomatic evidence brain leptomeningeal metastasis Ineligible locoregional treatment chemotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Transaminases great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN No uncontrolled hypercalcemia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study No known hypersensitivity systemic liposomal formulation compound chemically relate study drug No uncontrolled systemic disease infection No psychological , familial , sociological , geographical condition would preclude study No prior concurrent malignancy except adequately treat conebiopsied carcinoma situ cervix basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer biological therapy immune response modifiers No concurrent prophylactic hematopoietic growth factor Chemotherapy : See Disease Characteristics No prior chemotherapy recurrent disease No prior therapy camptothecin analogue At least 8 week since prior neoadjuvant adjuvant chemotherapy No concurrent anticancer cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Not specify Other : At least 30 day since prior experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
</DOC>